Comparison of bone marrow‑vs. adipose tissue‑derived mesenchymal stem cells for attenuating liver fibrosis
- Tianpao Hao
- Jingfeng Chen
- Shaoce Zhi
- Qiyu Zhang
- Gang Chen
- Fuxiang Yu
Published online on: October 18, 2017
Copyright: © Hao et al.
This is an open access article distributed under the terms of Creative Commons Attribution License.
Mesenchymal stem cell (MSC) therapy has emerged as a potential novel method of treating liver fibrosis. To date, bone marrow‑derived MSCs (BM‑MSCs) and adipose tissue‑derived MSCs (AD‑MSCs) have not been analyzed with respect to their ability to combat liver fibrosis. The present study aimed to compare the capabilities of BM‑MSCs and AD‑MSCs in the treatment of liver fibrosis. BM‑MSCs and AD‑MSCs were taken from male Sprague‑Dawley rats and cultured. Hepatic stellate cells (HSCs) were co‑cultured with either BM‑MSCs or AD‑MSCs, and the effects of BM‑MSCs or AD‑MSCs on the proliferation, activation and apoptosis of HSCs were determined. The secretion of a selected group of cytokines by BM‑MSCs and AD‑MSCs was measured using enzyme‑linked immunosorbent assays. Using a CCl4‑induced liver fibrosis animal model, the anti‑inflammatory and anti‑fibrotic effects of BM‑MSCs or AD‑MSCs against liver fibrosis in vivo were evaluated. The morphological examination and analysis of specific surface markers confirmed the successful preparation of BM‑MSCs and AD‑MSCs. Furthermore, the proliferation, activation and apoptosis of HSCs were significantly inhibited by BM‑MSCs and AD‑MSCs, with statistically greater reductions achieved by AD‑MSCs compared with BM‑MSCs. Direct comparison of the secretion of selected cytokines by BM‑MSCs and AD‑MSCs revealed that significantly higher levels of nerve growth factor and transforming growth factor‑β1 were secreted in the AD‑MSC culture medium, whereas levels of vascular endothelial growth factor and interleukin‑10 did not differ significantly between AD‑MSCs and BM‑MSCs. In vivo studies using a CCl4‑induced liver fibrosis model demonstrated that inflammatory activity and fibrosis staging scores were significantly lower in the MSC‑treated groups compared with controls. Although AD‑MSCs improved anti‑inflammatory and anti‑fibrotic effects compared with BM‑MSCs, these differences were not significant. Thus, the current study demonstrated that BM‑MSCs and AD‑MSCs are similarly effective at attenuating liver fibrosis by inhibiting the activation and proliferation of HSCs, as well as promoting the apoptosis of HSCs.